CEO Erez Israeli has projected double-digit growth for FY26, primarily on the back of semaglutide launches and pipeline ...

New epinephrine nasal spray dosage approved for pediatrics; FDA agree to review semaglutide for weight management; wearable defibrillator cleared to ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Bad reactions to popular weight-loss drugs, including Ozempic and Wegovy, are on track to soar by more than 350 per cent ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

It changed the way we diet, but now Weight Watchers’ fortunes seem to be fading. Katie Rosseinsky explores how the Ozempic ...

The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

Adverse reactions to weight-loss jabs are set to soar by more than 350% in a single year, according to the latest data.

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy-produced GLP-1 compounds are becoming much more affordable.

According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...